AIM Rule 26

Alliance Pharma PLC
13 August 2007


For Immediate Release                                            13 August  2007



                              ALLIANCE PHARMA PLC
                         ('Alliance' or 'the Company')

                         AIM Rule 26 Compliant Website


Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces
that the information required by Rule 26 of the AIM Rules for Companies
(February 2007) is available under the heading 'AIM Rule 26' within the
'Investor Relations' section on the Company's website at
www.alliancepharma.co.uk.



For further information:


Alliance Pharma plc                                        + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk

Numis Securities                                          + 44 (0) 20 7260 1000
David Poutney
Michael Meade

Buchanan Communications                                   + 44 (0) 20 7466 5000
Mark Court/Rebecca Skye Dietrich




Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 34 branded pharmaceutical products.



Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven.  Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.



Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.






                      This information is provided by RNS
            The company news service from the London Stock Exchange